Reuters logo
BRIEF-Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug
November 20, 2017 / 12:17 PM / 23 days ago

BRIEF-Intra-Cellular Therapies receives FDA fast track designation for Schizophrenia treatment drug

Nov 20 (Reuters) - Intra-cellular Therapies Inc:

* Intra-Cellular Therapies receives FDA fast track designation for lumateperone for the treatment of schizophrenia

* Intra-Cellular Therapies Inc - ‍food and drug administration granted fast track designation for lumateperone for treatment of Schizophrenia​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below